Logistics of therapy with the ibritumomab tiuxetan regimen

International Journal of Radiation Oncology Biology Physics

Volumn 66, Issue SUPPL. 2, 2006, Pages

  Meredith, Ruby F ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Ibritumomab tiuxetan; Non Hodgkin's lymphoma; Radioimmunotherapy

Indexed keywords

ANTIBODIES; DOSIMETRY; HEALTH CARE; PATIENT TREATMENT; RADIATION EFFECTS; RADIOISOTOPES;

IBRITUMOMAB TIUXETAN; NON-HODGKIN'S LYMPHOMA; RADIOIMMUNOTHERAPY;

RADIOTHERAPY;

CD20 ANTIGEN; IBRITUMOMAB TIUXETAN; INDIUM 111; RITUXIMAB;

ARTICLE; B CELL LYMPHOMA; CANCER RELAPSE; CLINICAL TRIAL; DIAGNOSTIC IMAGING; DRUG EFFICACY; DRUG SAFETY; HEALTH CARE PERSONNEL; HUMAN; NONHODGKIN LYMPHOMA; NUCLEAR MEDICINE; OUTPATIENT CARE; PATIENT CARE; PATIENT SELECTION; PRIORITY JOURNAL; RADIATION EXPOSURE; RADIATION PROTECTION; RADIATION SAFETY; RADIOIMMUNOTHERAPY; TREATMENT DURATION; TREATMENT PLANNING; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; DRUG ADMINISTRATION SCHEDULE; HEALTH PHYSICS; HUMANS; LICENSURE, HOSPITAL; LYMPHOMA, NON-HODGKIN; PATIENT CARE TEAM; PATIENT SELECTION; RADIATION PROTECTION; RADIOIMMUNOTHERAPY; YTTRIUM RADIOISOTOPES;

EID: 33748451271     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2006.06.009     Document Type: Article

References (9)

1. Zevalin (ibritumomab tiuxetan) prescribing information. Physicians' desk reference. 59th ed. (2005), Thomson PDR, Montvale, NJ 1738-1743
2. Wagner Jr. H.N., Wiseman G.A., Marcus C.S., et al. Administration guidelines for radioimmunotherapy of non-Hodgkin's lymphoma with (90)Y-labeled anti-CD20 monoclonal antibody. J Nucl Med 43 (2002) 267-272
3. 90Y) ibritumomab tiuxetan (Zevalin) radioimmunotherapy: Results from a Zevalin imaging registry. [Abstract]. Blood 104 (2004) 226b-227b
4. Juweid M.E., Stadtmauer E., Hajjar G., et al. Pharmacokinetics, dosimetry, and initial therapeutic results with 131I- and (111)In-/90Y-labeled humanized LL2 anti-CD22 monoclonal antibody in patients with relapsed, refractory non-Hodgkin's lymphoma. Clin Cancer Res 5 Suppl (1999) 3292s-3303s
5. Zelenetz A.D. Radioimmunotherapy for lymphoma. Curr Opin Oncol 11 (1999) 375-380
6. Schleien B., Birky B., and Slaback Jr. L. Handbook of health physics and radiological health. 3rd ed. (1998), Williams and Wilkins, Baltimore, MD
7. Nuclear Regulatory Commission. Occupational dose limits for adults (2002), US Nuclear Regulatory Commission, Washington, DC Title 10, part 20. 1201 and 67 FR 16304
8. Nuclear Regulatory Commission. Dose limits for individual members of the public (2002), US Nuclear Regulatory Commission, Washington, DC Title 10, part 20. 1301 and 67 FR 62872
9. Wiseman G., Leigh B., Witzig T., et al. Radiation exposure is very low to the family members of patients treated with yttrium-90 Zevalin anti-CD20 monoclonal antibody therapy for lymphoma. [Abstract]. Eur J Nucl Med 28 (2001) 1198